NCT04066712View on ClinicalTrials.gov

Renal PK Study of LC350189

PHASE1CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

November 19, 2019

Primary Completion Date

September 12, 2020

Study Completion Date

September 12, 2020

Conditions

GoutHyperuricemia

Interventions

DRUG

LC350189 200 mg

Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

Sponsors

Lead Sponsor

All Listed Sponsors

lead

LG Chem

INDUSTRY

NCT04066712 - Renal PK Study of LC350189 | Biotech Hunter | Biotech Hunter